In consultation: Guidance and quality standards
Showing 11 to 16 of 16
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Gender Incongruence Services for Children and Young People | Topic engagement | Quality standard | |
| Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Elamipretide for treating Barth syndrome in people of any age [ID6545] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487] | Draft guidance | Technology appraisal guidance | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Draft guidance | Technology appraisal guidance |